Phaseline

Companies › Vaccinex

Vaccinex: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Avelumab
Programmed cell death 1 ligand 1 other
CD274Phase 1Metastatic Pancreatic AdenocarcinomaDec 2028
Pepinemab
Semaphorin-4D inhibitor
SEMA4DPhase 1Metastatic Pancreatic Adenocarcinoma; Squamous Cell Carcinoma of the Head and Neck; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Dec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03690986PepinemabPhase 1Squamous Cell Carcinoma of the Head and NeckOncologyApr 2027
NCT05102721AvelumabPhase 1Metastatic Pancreatic AdenocarcinomaOncologyDec 2028
NCT05102721PepinemabPhase 1Metastatic Pancreatic AdenocarcinomaOncologyDec 2028
NCT03769155PepinemabPhase 1Pathologic Stage IIIB Cutaneous Melanoma AJCC v8OncologyDec 2032

From the company's SEC filings

Cash of $1m on 2024-12-31; operating cash outflow about $16m a year; runway about 1 months at that burn, to Jan 2025

Private offerings reported to the SEC (Form D)

Targets

CD274 (1) SEMA4D (1)

Companies with the same targets

AstraZeneca Pfizer IO Biotech ImmuneOncia Therapeutics Akeso Roche Biotheus Suzhou Suncadia Biopharmaceuticals Shine-On Biomedical 3D Medicines (Sichuan)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.